The primary occurrence of BRAFV600E is a rare clonal event in papillary thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 2, 2012, Pages 517-524

  Guerra, Anna ^a   Sapio, Maria Rosaria ^a   Marotta, Vincenzo ^b   Campanile, Elisabetta ^a   Rossi, Stefania ^c   Forno, Irene ^c   Fugazzola, Laura ^d   Budillon, Alfredo ^e   Moccia, Tania ^e   Fenzi, Gianfranco ^b   Vitale, Mario ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PROTEIN NRAS; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CANCER CELL CULTURE; CELL HETEROGENEITY; CELL SELECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA SEQUENCE; GENE MUTATION; HETEROZYGOSITY; MOLECULAR CLONING; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PYROSEQUENCING; SEQUENCE ANALYSIS; THYROID PAPILLARY CARCINOMA;

AMINO ACID SUBSTITUTION; BASE SEQUENCE; CARCINOMA; CLONE CELLS; DNA MUTATIONAL ANALYSIS; GENE FREQUENCY; GLUTAMIC ACID; HUMANS; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; VALINE;

EID: 84856798619     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0618     Document Type: Article

References (40)

1. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404 (Pubitemid 37452745)
2. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF-signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457 (Pubitemid 36373628)
3. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561-4567 (Pubitemid 36951030)
4. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D 2004 BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 89:1365-1368 (Pubitemid 38368438)
5. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE 2006 Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 91:3603-3610 (Pubitemid 44402144)
6. Namba H, Rubin SA, Fagin JA 1990 Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4:1474-1479 (Pubitemid 20356608)
7. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C 2003 Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88:2745-2752 (Pubitemid 36724451)
8. Guerra A, Sapio MR, Marotta V, Campanile E, Moretti MI, Deandrea M, Motta M, Limone PP, Fenzi G, Rossi G, Vitale M 2011 Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr J 58:31-38
9. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Máximo V, Botelho T, Seruca R, Sobrinho-Simões M 2003 BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578-4580
10. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE, Fagin JA 2005 Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65: 4238-4245 (Pubitemid 40775662)
11. Kim CS, Zhu X 2009 Lessons from mouse models of thyroid cancer. Thyroid 19:1317-1331
12. Park YJ, Kim YA, Lee YJ, Kim SH, Park SY, Kim KW, Chung JK, Youn YK, Kim KH, Park do J, Cho BY 2010 Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings. Head Neck 32:38-45
13. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S 2010 B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA 107:10649-10654
14. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G 1990 PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557-563
15. Unger K, Zitzelsberger H, Salvatore G, Santoro M, Bogdanova T, Braselmann H, Kastner P, Zurnadzhy L, Tronko N, Hutzler P, Thomas G 2004 Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. J Clin Endocrinol Metab 89:4272-4279 (Pubitemid 39244425)
16. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, Nonaka D, Mortarini R, Parmiani G, Fais S, Anichini A 2006 Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25:3357-3364 (Pubitemid 43877040)
17. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S 2011 Targeting BRAFV600E with PLX4720 displays potent anti-migratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 16:296-309
18. Nucera C, Goldfarb M, Hodin R, Parangi S 2009 Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta 1795:152-161
19. Rosai J, Carcangiu ML, De Lellis RA 1992 Tumors of the thyroid gland. In: Rosai J, ed. Atlas of tumor pathology, third series, fascicle 5. Washington DC: Armed Forces Institute of Pathology; 49-62
20. Di Matola T, Mueller F, Fenzi G, Rossi G, Bifulco M, Marzano LA, Vitale M 2000 Serum withdrawal-induced apoptosis in thyroid cells is caused by loss of fibronectin-integrin interaction. J Clin Endocrinol Metab 85:1188-1193 (Pubitemid 32269370)
21. Illario M, Amideo V, Casamassima A, Andreucci M, di Matola T, Miele C, Rossi G, Fenzi G, Vitale M 2003 Integrin-dependent cell growth and survival are mediated by different signals in thyroid cells. J Clin Endocrinol Metab 88:260-269 (Pubitemid 36115176)
22. Marotta V, Guerra A, Sapio MR, Campanile E, Motta M, Fenzi G, Rossi G, Vitale M 2010 Growing thyroid nodules with benign histology and RET rearrangement. Endocr J 57:1081-1087
23. Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SK 2008 Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol 215: 145-154 (Pubitemid 351786033)
24. Vasko V, Hu S, Wu G, Xing JC, Larin A, Savchenko V, Trink B, Xing M 2005 High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 90:5265-5269 (Pubitemid 41262284)
25. Abrosimov A, Saenko V, Rogounovitch T, Namba H, Lushnikov E, Mitsutake N, Yamashita S 2007 Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer 120:196-200 (Pubitemid 44901936)
26. Wang YL, Wang JC, Wu Y, Zhang L, Huang CP, Shen Q, Zhu YX, Li DS, Ji QH 2008 Incidentally simultaneous occurrence of RET/PTC, H4-PTEN and BRAF mutation in papillary thyroid carcinoma. Cancer Lett 263:44-52
27. Vriens MR, Moses W, Weng J, Peng M, Griffin A, Bleyer A, Pollock BH, Indelicato DJ, Hwang J, Kebebew E 2011 Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. Cancer 117:259-267
28. Henderson YC, Shellenberger TD, Williams MD, El-Naggar AK, Fredrick MJ, Cieply KM, Clayman GL 2009 High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 15:485-491
29. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379 (Pubitemid 41759286)
30. Lee JH, Lee ES, Kim YS 2007 Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110:38-46
31. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R 2006 Correlation between B-RAF V600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13:455-464 (Pubitemid 43886668)
32. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK 2005 The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 63:588-593 (Pubitemid 41626756)
33. Sapio MR, Posca D, Raggioli A, Guerra A, Marotta V, Deandrea M, Motta M, Limone PP, Troncone G, Caleo A, Rossi G, Fenzi G, Vitale M2007 Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 66:678-683 (Pubitemid 46699541)
34. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A 2009 BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56:89-97
35. Xing M 2010 Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321:86-93
36. Wang Y, Ji M, Wang W, Miao Z, Hou P, Chen X, Xu F, Zhu G, Sun X, Li Y, Condouris S, Liu D, Yan S, Pan J, Xing M 2008 Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocr Relat Cancer 15:183-190 (Pubitemid 351449738)
37. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R 2009 BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27:2977-2982
38. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899
39. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
40. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719